Idioma:

Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks

Palechor-Ceron, Nancy ; Krawczyk, Ewa ; Dakic, Aleksandra ; Simic, Vera ; Yuan, Hang ; Blancato, Jan ; Wang, Weisheng ; Hubbard, Fleesie ; Zheng, Yun-Ling ; Dan, Hancai ; Strome, Scott ; Cullen, Kevin ; Davidson, Bruce ; Deeken, John F ; Choudhury, Sujata ; Ahn, Peter H ; Agarwal, Seema ; Zhou, Xuexun ; Schlegel, Richard ; Furth, Priscilla A ; Pan, Chong-Xian ; Liu, Xuefeng

Cells (Basel, Switzerland), 2019-10, Vol.8 (11), p.1327 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
Autor: Palechor-Ceron, Nancy ; Krawczyk, Ewa ; Dakic, Aleksandra ; Simic, Vera ; Yuan, Hang ; Blancato, Jan ; Wang, Weisheng ; Hubbard, Fleesie ; Zheng, Yun-Ling ; Dan, Hancai ; Strome, Scott ; Cullen, Kevin ; Davidson, Bruce ; Deeken, John F ; Choudhury, Sujata ; Ahn, Peter H ; Agarwal, Seema ; Zhou, Xuexun ; Schlegel, Richard ; Furth, Priscilla A ; Pan, Chong-Xian ; Liu, Xuefeng
Assuntos: Amides ; Animal models ; Animals ; Biological Specimen Banks - trends ; Biology ; Biopsy ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Squamous Cell - pathology ; Cell culture ; Cell Culture Techniques - methods ; Cell Differentiation ; Cell Line ; Cell Line, Tumor ; Cellular Reprogramming - physiology ; Cellular Reprogramming Techniques - methods ; Chemotherapy ; Clinical trials ; Coculture Techniques - methods ; conditionally reprogrammed cells ; Cryopreservation ; Drug resistance ; Enzyme inhibitors ; Epigenetics ; Epithelial cells ; Epithelial Cells - pathology ; FDA approval ; Gene expression ; Genetic engineering ; Genomics ; Histopathology ; Humans ; Karyotypes ; Kinases ; living biobanks ; Lung carcinoma ; Lung Neoplasms - pathology ; Lymphoma ; Male ; Medical research ; Medicine ; Metabolomics ; Metastasis ; Models, Biological ; Mutation ; Non-small cell lung carcinoma ; Oncology ; Organoids ; patient-derived cancer models ; Patients ; Phenotypes ; Pleural effusion ; Precision medicine ; Precision Medicine - methods ; Prostate cancer ; Prostatic Neoplasms - pathology ; Proteomics ; Pyridines ; Regenerative medicine ; Response rates ; Review ; Rho-associated kinase ; Small cell lung carcinoma ; Squamous cell carcinoma ; Stem cells ; Transfection ; Tumor cell lines ; Tumors ; Urinary Bladder Neoplasms - pathology
É parte de: Cells (Basel, Switzerland), 2019-10, Vol.8 (11), p.1327
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
Descrição: Traditional cancer models including cell lines and animal models have limited applications in both basic and clinical cancer research. Genomics-based precision oncology only help 2-20% patients with solid cancer. Functional diagnostics and patient-derived cancer models are needed for precision cancer biology. In this review, we will summarize applications of conditional cell reprogramming (CR) in cancer research and next generation living biobanks (NGLB). Together with organoids, CR has been cited in two NCI (National Cancer Institute, USA) programs (PDMR: patient-derived cancer model repository; HCMI: human cancer model initiatives. HCMI will be distributed through ATCC). Briefly, the CR method is a simple co-culture technology with a Rho kinase inhibitor, Y-27632, in combination with fibroblast feeder cells, which allows us to rapidly expand both normal and malignant epithelial cells from diverse anatomic sites and mammalian species and does not require transfection with exogenous viral or cellular genes. Establishment of CR cells from both normal and tumor tissue is highly efficient. The robust nature of the technique is exemplified by the ability to produce 2 × 10 cells in five days from a core biopsy of tumor tissue. Normal CR cell cultures retain a normal karyotype and differentiation potential and CR cells derived from tumors retain their tumorigenic phenotype. CR also allows us to enrich cancer cells from urine (for bladder cancer), blood (for prostate cancer), and pleural effusion (for non-small cell lung carcinoma). The ability to produce inexhaustible cell populations using CR technology from small biopsies and cryopreserved specimens has the potential to transform biobanking repositories (NGLB: next-generation living biobank) and current pathology practice by enabling genetic, biochemical, metabolomic, proteomic, and biological assays, including chemosensitivity testing as a functional diagnostics tool for precision cancer medicine. We discussed analyses of patient-derived matched normal and tumor models using a case with tongue squamous cell carcinoma as an example. Last, we summarized applications in cancer research, disease modeling, drug discovery, and regenerative medicine of CR-based NGLB.
Editor: Switzerland: MDPI AG
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks

Switzerland: MDPI AG

Buscando em bases de dados remotas. Favor aguardar.